SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(van Vollenhoven Ronald)
 

Sökning: WFRF:(van Vollenhoven Ronald) > (2015-2019) > A Multi-Biomarker D...

  • Hambardzumyan, KarenKarolinska Institutet (författare)

A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure

  • Artikel/kapitelEngelska2017

Förlag, utgivningsår, omfång ...

  • 2017-03-31
  • Wiley,2017

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:37550da3-dd57-4743-9b5d-3b1ec4df7062
  • https://lup.lub.lu.se/record/37550da3-dd57-4743-9b5d-3b1ec4df7062URI
  • https://doi.org/10.1002/art.40019DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:135698594URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • Objective: To investigate whether the Multi-Biomarker Disease Activity (MBDA) score predicts optimal add-on treatment in patients with early rheumatoid arthritis (RA) who were inadequate responders to MTX (MTX-IRs). Methods: We analyzed data from 157 MTX-IRs (with a Disease Activity Score using the erythrocyte sedimentation rate [DAS28-ESR] >3.2) from the Swedish Pharmacotherapy (SWEFOT) trial who were randomized to receive triple therapy (MTX plus sulfasalazine plus hydroxychloroquine) versus MTX plus infliximab. The MBDA score as a predictor of the subsequent DAS28-based response to each second-line treatment was analyzed at randomization with the Breslow-Day test for 2 × 2 groups, using both validated categories (low [<30], moderate [30–44], and high [>44]) and dichotomized categories (lower [≤38] versus higher [>38]). Results: Among the 157 patients, 12% had a low MBDA score, 32% moderate, and 56% high. Of those with a low MBDA score, 88% responded to subsequent triple therapy, and 18% responded to MTX plus infliximab (P = 0.006); for those with a high MBDA score, the response rates were 35% and 58%, respectively (P = 0.040). When using 38 as a cutoff for the MBDA score (29% patients with lower scores versus 71% with higher scores), the differential associations with response to triple therapy versus MTX plus infliximab were 79% versus 44% and 36% versus 58%, respectively (P = 0.001). Clinical and inflammatory markers had poorer predictive capacity for response to triple therapy or MTX plus infliximab. Conclusion: In patients with RA who had an inadequate response to MTX, the MBDA score categories were differentially associated with response to subsequent therapies. Thus, patients with post-MTX biochemical improvements (lower MBDA scores) were more likely to respond to triple therapy than to MTX plus infliximab. If confirmed, these results may help to improve treatment in RA.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Saevarsdottir, SaedisKarolinska Institutet (författare)
  • Forslind, KristinaLund University,Lunds universitet,Kliniska Vetenskaper, Helsingborg,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Clinical Sciences, Helsingborg,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Helsingborg Hospital(Swepub:lu)med-kfi (författare)
  • Petersson, Ingemar F.Lund University,Lunds universitet,Ortopedi, Lund,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tillämpad epidemiologi,Forskargrupper vid Lunds universitet,Orthopaedics (Lund),Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Applied epidemiology,Lund University Research Groups(Swepub:lu)ort-ipe (författare)
  • KARLSSON WALLMAN, JOHANLund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lund Arthritis Research Group (LARG),Forskargrupper vid Lunds universitet,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups(Swepub:lu)med-jnk (författare)
  • Ernestam, SofiaKarolinska Institute (författare)
  • Bolce, Rebecca JCrescendo Bioscience Inc. (författare)
  • van Vollenhoven, Ronald FKarolinska Institutet (författare)
  • Karolinska InstitutetKliniska Vetenskaper, Helsingborg (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Arthritis & Rheumatology: Wiley69:5, s. 953-9632326-51912326-5205

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy